Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the future treatment of solid and hematologic cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that its oral non-covalent BTK-inhibitor, SNS-062, treats ibrutinib-resistant chronic lymphocytic leukemia. Sunesis is also supporting investigator-led studies of vosaroxin in acute myeloid leukemia. Source
No articles found.
Genobank is the first privacy-preserving personal DNA Kit that guarantees consumer...
Genobank is the first privacy-preserving person...
Stericycle is a multinational business-to-business services company with a core pu...
Stericycle is a multinational business-to-busin...
We are a pharmaceutical company dedicated to the development of best-in-class ther...
We are a pharmaceutical company dedicated to th...
Rockwell Medical (NASDAQ: RMTI) is a fully-integrated biopharmaceutical company ta...
Rockwell Medical (NASDAQ: RMTI) is a fully-inte...
PhaseBio is a clinical-stage biopharmaceutical company focused on the development ...
PhaseBio is a clinical-stage biopharmaceutical ...
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, dev...
Cytokinetics is a late-stage biopharmaceutical ...
Unum Therapeutics is a clinical-stage biopharmaceutical company focused on develop...
Unum Therapeutics is a clinical-stage biopharma...
Join the National Investor Network and get the latest information with your interests in mind.